Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
Ria Lassaunière, Charlotta Polacek, Anders Frische, Lasse Boding, Susanne Gjørup Sækmose, Morten Rasmussen, Anders Fomsgaard
Abstract
the observed decrease in population neutralizing antibody titers corresponds to the decrease in vaccine efficacy against polymerase chain reaction-confirmed Omicron infection in Denmark and symptomatic Omicron infection in the United Kingdom. Taken together, vaccine-induced protective antibody responses following a second and third dose of BNT162b2 are transient and additional booster doses may be necessary, particularly in older people; however, conserved T-cell immunity and nonneutralizing antibodies may still provide protection against hospitalization and death.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)AntibodyNeutralizing antibody2019-20 coronavirus outbreakMessenger RNAMedicineChemistryImmunologyGeneInternal medicineInfectious disease (medical specialty)DiseaseBiochemistryOutbreakSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesBacillus and Francisella bacterial research